id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15240 R63066 |
Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
3.19 [1.85;5.50] C excluded (control group) |
16/290 95/5,288 | 111 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15233 R63067 |
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 2.38 [1.40;4.06] | 16/290 528/22,203 | 544 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8589 R48828 |
Richards (Topiramate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.18 [0.01;3.16] C excluded (control group) |
0/28 13/149 | 13 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8590 R48829 |
Richards (Topiramate) (Controls unexposed, NOS) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No | 0.42 [0.03;6.93] C | 0/28 11,841/286,966 | 11,841 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8582 R48827 |
Bromley (Topiramate), 2016 | Maladaptive behavior: Attention (BASC) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 1.00 [0.43;2.31] | -/27 -/55 | - | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8615 R48830 |
Rihtman (Topiramate) (Mixed indications), 2012 | Cognitive problems/inattention (Parent questionnaire) (Conners' rating scale - revised) (mean age around 4 years old) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Matched | 4.37 [0.91;21.04] | -/8 -/18 | - | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.78 [0.89;3.56] | 12,385 | 353 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Epilepsy) (Controls unexposed, sick; 2: Topiramate) (Controls unexposed, NOS) (Indications NOS; 3: Topiramate; 4: Topiramate) (Mixed indications;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8589, 15240